ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating

ProKidney, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on the stock and has a $3.00 price target.

Judah Frommer has given his Hold rating due to a combination of factors related to ProKidney’s clinical and commercial trajectory. The company’s decision to cut the total enrollment target in the PROACT1 trial while maintaining statistical power keeps the core efficacy thesis intact, but it also pushes the timing of the confirmatory analysis further out, delaying key de‑risking milestones. While the unchanged assumptions for both the surrogate and confirmatory endpoints are reassuring from a scientific standpoint, the extended duration of the pivotal component of the study introduces additional execution and timeline risk that tempers near‑term upside.

At the same time, the updated plan allows management to concentrate more resources on preparing for a potential BLA submission and commercial rollout that could be supported by the surrogate endpoint readout expected in 2Q27. With the enrollment target for the surrogate analysis unchanged and mid‑2026 completion still anticipated, there remains a clear path to an accelerated approval scenario, but it is neither imminent nor fully derisked. Taken together, the balance between a preserved long‑term opportunity and delayed, uncertain confirmation of benefit supports a neutral stance rather than a more decisive positive or negative rating, leading Frommer to maintain a Hold recommendation.

Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, Incyte, and PTC Therapeutics. According to TipRanks, Frommer has an average return of 1.6% and a 51.59% success rate on recommended stocks.

In another report released yesterday, TipRanks – Anthropic also initiated coverage with a Hold rating on the stock with a $2.00 price target.